Education
About Us
Working with TipRanks
Follow Us
Clinigence Holdings (NUTX)
NASDAQ:NUTX
Top Page
Clinigence Holdings
(NASDAQ:NUTX)
73Outperform
Positive Factors
Expansion Strategy
The company opened four new facilities in 2024, expanding its network to 24 micro-hospitals, demonstrating its growth and expansion strategy.
Financial Performance
Nutex reported revenue of $257.6M, significantly higher than the previous year's $69.7M, driven by successful rate arbitration with payers.
Financial Position
Nutex holds more cash than long-term debt, which reflects a strong financial position.
Negative Factors
Market Position
Shares currently trade at an EV/revenue multiple of 0.4x our 2025 estimate, below the peer average of 1.6x, excluding NUTX.
Stock Valuation
Shares currently trade at a discount to peers, reflecting the early stage and unproven nature of Nutex's business model.
Clinigence Holdings (NUTX) vs. S&P 500 (SPY)
Market Cap
$652.30M
Dividend YieldN/A
Average Volume (3M)127.42K
Price to Earnings (P/E)12.7
Beta (1Y)2.01
Revenue Growth93.80%
EPS GrowthN/A
CountryUS
Employees800
SectorHealthcare
Sector Strength58
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)9.27
Shares Outstanding5,528,448
10 Day Avg. Volume146,121
30 Day Avg. Volume127,421
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.69
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$125.00Price Target Upside9.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Clinigence Holdings Business Overview & Revenue Model
Company DescriptionNutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.
How the Company Makes MoneyClinigence Holdings makes money primarily through the sale of its technology solutions to healthcare providers and organizations. The company's revenue model includes subscription-based fees for its software platforms, which offer analytics and population health management tools. Additionally, Clinigence may generate income through consulting services and partnerships with healthcare providers who seek to implement value-based care initiatives. These revenue streams are supported by the company's ability to deliver actionable insights and data-driven strategies that help healthcare organizations improve efficiency and patient outcomes.
Clinigence Holdings Financial Statement Overview
Summary
Clinigence Holdings has shown strong revenue growth and improved profitability with significant increases in total revenue and net income. However, high leverage and fluctuating EBIT and EBITDA margins pose financial risks. The company's cash flow position has improved with positive free cash flow, indicating better financial health.Income Statement
The company's revenue has shown significant growth from 2019 to 2024, with a notable increase in Total Revenue in 2024 to $479.9 billion. Gross Profit Margin and Net Profit Margin have improved significantly from negative figures in 2023 to strong positive values in 2024, indicating improved operational efficiency and profitability. However, the EBIT and EBITDA margins have fluctuated, suggesting some instability in operational performance over the years.65
Positive
Balance Sheet
The Debt-to-Equity Ratio is relatively high, indicating significant leverage, which could pose financial risks. Despite this, the company has a strong equity base with a Stockholders' Equity of $201.9 billion in 2024. The Equity Ratio has improved over the years, suggesting better asset financing through equity rather than debt.58
Neutral
Cash Flow
Operating Cash Flow has been consistently positive, showing strong cash-generating capability. The Free Cash Flow turned positive in 2024, signaling an improvement in financial health. However, the Free Cash Flow Growth Rate fluctuated significantly in previous years, pointing to potential volatility in cash flow management.72
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 479.95M | 247.65M | 219.29M | 331.53M | 273.42M | Gross Profit |
| 196.26M | 34.77M | 13.45M | 179.28M | 271.60M | EBIT |
| 130.62M | -31.77M | -5.14M | 170.26M | 152.33M | EBITDA |
| 148.65M | -14.58M | -393.96M | 183.45M | -5.12M | Net Income Common Stockholders |
| 52.18M | -45.79M | -432.74M | 132.59M | 105.97M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 43.58B | 22.00M | 34.26M | 36.12M | 25.51M | Total Assets |
| 655.32B | 398.25M | 431.75M | 394.65M | 308.55M | Total Debt |
| 314.28B | 275.76M | 267.20M | 178.55M | 150.12M | Net Debt |
| 270.70B | 253.75M | 232.95M | 142.43M | 124.61M | Total Liabilities |
| 453.43B | 319.14M | 311.42M | 203.07M | 161.19M | Stockholders Equity |
| 201.89B | 61.45M | 95.86M | 114.65M | 85.81M |
| Cash Flow | Free Cash Flow | |||
| 23.15B | -8.24M | 35.97M | 136.51M | 20.07M | Operating Cash Flow |
| 23.15B | 1.26M | 50.61M | 173.43M | 81.26M | Investing Cash Flow |
| -2.67B | -11.24M | -4.34M | -36.98M | -61.19M | Financing Cash Flow |
| 1.09M | -2.27M | -48.13M | -125.85M | -2.56M |
Clinigence Holdings Technical Analysis
Positive
114.63
Price Trends
80.61
Positive
61.09
Positive
41.19
Positive
Market Momentum
11.18
Positive
54.20
Neutral
25.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Positive. The current price of 114.63 is below the 20-day moving average (MA) of 120.18, above the 50-day MA of 80.61, and above the 200-day MA of 41.19, indicating a neutral trend. The MACD of 11.18 indicates Positive momentum. The RSI at 54.20 is Neutral, neither overbought nor oversold. The STOCH value of 25.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUTX.
Clinigence Holdings Risk Analysis
Clinigence Holdings disclosed 62 risk factors in its most recent earnings report. Clinigence Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clinigence Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $652.30M | 12.72 | 50.22% | ― | 93.80% | ― | |
60 Neutral | $261.35M | ― | -36.07% | ― | ― | -7.93% | |
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% | |
50 Neutral | $349.64M | ― | 344.74% | ― | -47.32% | -26.67% | |
48 Neutral | $319.89M | ― | -79.69% | ― | -33.43% | 8.94% | |
46 Neutral | $361.63M | ― | -39.07% | ― | ― | 0.42% | |
33 Underperform | $249.40M | ― | -139.56% | ― | ― | -33.79% |
* Healthcare Sector Average
Performance Comparison
NUTX
Clinigence Holdings
114.63
107.83
1585.74%
ATYR
aTyr Pharma
3.60
1.99
123.60%
IVA
Inventiva
3.38
0.08
2.42%
CMPX
Compass Therapeutics
1.89
0.19
11.18%
OLMA
Olema Pharmaceuticals
5.62
-5.05
-47.33%
CADL
Candel Therapeutics
5.28
-3.74
-41.46%
Clinigence Holdings Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: 143.74%|
Next Earnings Date:May 19, 2025
Earnings Call Sentiment Positive
The call highlighted strong financial growth, successful arbitration outcomes, and effective debt management, despite challenges posed by the No Surprises Act and the operational burden of the arbitration process.Q4-2024 Updates
Positive Updates
Exceptional Revenue Growth
For the full year of 2024, total revenue reached $479.9 million, up 94% from $247.6 million in 2023.
Significant EBITDA Increase
Adjusted EBITDA increased from $10.8 million in 2023 to $123.7 million in 2024, up over 1,000%.
Net Income Turnaround
Full year 2024 net income was $52 million compared to a loss of $46 million in 2023.
Hospital Expansion
Opened four new hospitals in 2024, bringing the total to 24 hospitals across 11 states.
Debt Management
Long-term debt decreased from $26 million in 2023 to $22 million in 2024, emphasizing fiscal responsibility.
Arbitration Process Success
Achieved an 80% win rate in arbitration, resulting in significant revenue recovery, with a 150% to 250% increase in reimbursement on the facility collection side.
Negative Updates
Impact of No Surprises Act
The flawed implementation of the No Surprises Act and its arbitration process has hit revenue per patient reimbursement hard, with insurer payments for emergency services dropping roughly 30% in 2022.
Arbitration Process Challenges
The arbitration process is costly, labor-intensive, and time-consuming, posing a significant operational challenge.
Company Guidance
During the Nutex Health Fourth Quarter 2024 Earnings Call, significant financial metrics were highlighted, demonstrating the company's robust performance. Total revenue for the full year reached $479.9 million, marking a 94% increase from 2023's $247.6 million. The adjusted EBITDA saw an impressive surge from $10.8 million in 2023 to $123.7 million in 2024, reflecting a growth of over 1,000%. Net income also improved, reaching $52 million in 2024, compared to a loss of $46 million the previous year. Patient volume rose by 17%, with total hospital visits increasing from 144,000 in 2023 to 168,000 in 2024, driven by a 6.5% growth from mature hospitals. Despite opening four new hospitals, long-term debt was efficiently managed, increasing only slightly in the current portion from $10.8 million in 2023 to $14 million in 2024, while net long-term debt decreased from $26 million to $22 million. These metrics underscore Nutex Health's successful expansion strategy and fiscal discipline amidst challenges like the No Surprises Act and its arbitration process.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.